Dr. Mitchell has more than 40 years of experience practicing ophthalmology as a surgeon and clinician, served as president and managing partner of McCannel Eye Clinic for 17 years. Dr. Mitchell has the know-how for managing a multi-million dollar clinical practice with thirty employees, an ambulatory surgical facility, and an ophthalmology clinic. Jim is skilled in managing, motivating, and coordinating senior or junior physicians, technicians, and support staff.  His expertise will position Sonder Research X’s mission toward practical products for eye care professionals.  He received his Bachelor of Arts (A.B.) degree from Harvard College at Harvard University and earned his medical degree (M.D.) from Duke University School of Medicine.    

Dr. Pena, former Assistant Professor of Ophthalmology at Weill Cornell Medicine (WCM) and Principal Investigator at Dyson Vision Research Institute. John is a physician-scientist, with an M.D. degree from Weill Cornell Medical College, a Ph.D. degree from The Rockefeller University, and residency training in ophthalmology completed at WCM and New York-Presbyterian Hospital. He trained with Thomas Tuschl, Professor at Rockefeller University, and HHMI for his Ph.D., where his team developed an innovative method to image small RNAs in biopsy tissue sections. 

Mr. Remmel is currently a partner of the law firm Pryor Cashman LLP. Mr. Remmel serves as a director of Atossa Therapeutics, Inc.  (NASDAQ: ATOS), where he sits on the Audit Committee and Nominating and Governance Committee.  Mr. Remmel serves as well as a director of CytoDel, Inc., an early-stage biopharmaceutical company developing products for bio-defense, neuronal drug delivery, and musculoskeletal and aesthetic medicine. He received his J.D. from the Washington & Lee University School of Law in 1979 and his B.A. from Princeton University in 1975. He currently is a doctoral candidate in the Graduate School of Life Sciences of the University of Utrecht, in the Department of Clinical and Translational Oncology, with a thesis project in hyperplasia and early- stage breast cancer.

Mr. Thaw is the President and CEO of Bulbtronics  Inc., an international distributor of technical and specialty light sources and related products to the medical, scientific, entertainment, and industrial markets. Mr. Thaw was a member of the Board of Directors of Marina Biotech, Inc. from June 1991 to July 2010.  Marina Biotech develops therapeutics and drug delivery technologies, including through the utilization of RNAi-related technologies.  Mr. Thaw also served as Chairman of the Board and as a member of the Audit and Compensation Committees of the Board of Directors. He was formerly a  practicing attorney and was admitted to the bar of the State of New York (1978) and the California State Bar (1983).  Mr. Thaw served as a member of the Board of Directors of SafeNet, Inc. (1990-2007), a company that designs, manufactures, and markets information security systems, products, and services that protect and secure digital identities, communications, and intellectual property. Mr. Thaw holds a B.B.A. degree in Banking and Finance from Hofstra University and a J.D. degree from the Hofstra University School of Law.

Dr. Wheeler has extensive experience in the practice of medicine and the creation and building of biotechnology companies. Mark was a founding investor in Ception Therapeutics, LevTech, and Hemosonics, and served on their boards from inception to sale. He also served on the board of Silver Creek Pharmaceuticals until 2020. He has been deeply involved in African philanthropy and is a long term supporter of Tostan, a Senagalese based NGO focused on human rights. He did his undergraduate studies at Princeton University and his medical studies at Wake Forest Medical School.